Imuran (Azathioprine)

Azathioprine is converted to 6‑mercaptopurine, which blocks purine synthesis needed for DNA replication. This limits the proliferation of rapidly dividing immune cells, especially lymphocytes, thereby dampening the immune response and reducing inflammation.

The dose of Imuran is individualized. A qualified prescriber determines the appropriate amount based on the patient’s condition, weight, laboratory values, and response to therapy. Patients should follow the prescribing clinician’s instructions exactly.

Azathioprine is classified as a pregnancy‑category drug with limited data. It should only be used when the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended unless the prescriber deems it essential.

To request Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Imuran and mycophenolate mofetil are immunosuppressants used in transplantation and autoimmune diseases. Imuran is a purine analogue that inhibits lymphocyte proliferation, while mycophenolate blocks inosine monophosphate dehydrogenase, affecting guanine synthesis. Choice depends on efficacy, tolerability, drug‑interaction profile and physician preference.

Imuran tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Imuran is taken orally, usually with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals to minimise gastrointestinal discomfort.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity, increased susceptibility to serious infections, pancreatitis, and a heightened long‑term risk of certain malignancies such as lymphoma or skin cancer.

Imuran should be avoided in individuals with known hypersensitivity to azathioprine, severe hepatic impairment, active uncontrolled infections, or those who are pregnant unless the benefit outweighs the risk. Patients with low TPMT activity may also be contraindicated due to heightened toxicity.